Rapid Determination of Montelukast in Human Plasma by LC-ESI-MS/MS and Its Application to a Bioequivalence Study

Capillary Zone Electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies

“…This fact indicates a suitability of the analytical method for bioavailability studies. The plasma elimination halflife, t 0.5 was found to be 6.1 ± 0.4 h and is similar to t 0.5 = 5.4 and 7.6 h reported previously [17,20]. However, literature data reported a wide range of t 0.5 values of CLPM, from 1.9 ± 0.9 h after a dose of 600 mg CLP [16] to 10.0 ± 2.2 h following the administration of 75 mg CLP [7].…”

“…The value of LOQ in plasma for CLPM has proven to be similar to LOQ of 0.2 mg/L obtained by HPLC-UV method and reported by Souri et al [8]. Very low values of LOQ of 0.05 mg/L can be obtained by a sensitive LC-MS-MS method [17]. However, the elaborated CZE method proved to be sensitive enough to determine the concentrations of CLPM in patients' plasma up to 24 h (Fig.…”

“…2A3 and B3). Unchanged CLP could only occasionally be detected in studies using HPLC-MS-MS methods [16,17]. Rapid absorption of CLP from tablets in GI tract is best demonstrated by the early appearance in plasma of CLPM (Fig.…”

“…The methods were applied for bioavailability studies of CLP in healthy volunteers [8,9]. Moreover, GC-MS, LC-MS and LC-MS-MS methods were reported for the determination of CLPM in biological fluids [7,[14][15][16][17]. However, the methods required time and solvent consuming extraction from biological matrix [7,14] and derivatization of the analyte [14].…”

Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry

“…Up to now, there has only been one reported determination method for icotinib in plasma of beagle dogs [9]. The method can receive 0.5 ng/mL of LLoQ using sample preparation procedure of protein precipitation, which easily generates strong matrix effect [10]. Based on our preliminary pharmacokinetic study results (unpublished results), detection of icotinib in human plasma requires a LLoQ of 0.1 ng/mL.…”